No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
H.C. Wainwright Downgrades Carisma Therapeutics(CARM.US) to Hold Rating
HC Wainwright & Co. Downgrades CARISMA Therapeutics to Neutral
Carisma Downgraded by Baird Over Lack of Near-term Catalysts
D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $12 Price Target
Carisma Therapeutics Cut to Neutral From Outperform by Baird
Carisma Therapeutics Price Target Cut to $1.00/Share From $10.00 by Baird
Unlock the Full List